EUR/USD 1.16487
-0.208%
Gold 4600.44
-1.249%
Oil 82.113
1.776%
USD/JPY 159.378
0.111%
GBP/USD 1.35898
-0.419%
GBP/JPY 216.593
-0.306%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
According to Nikkei, Terra Charge will launch charging stations using the North American Charging Standard (NACS) in the fiscal year beginning April 2028.According to Nikkei, Terra Charge in Japan will launch electric vehicle charging stations compatible with Tesla.Iranian nuclear energy chief Eslami: Trumps threat to bomb so-called secret Iranian nuclear facilities exposes that international organizations have become "pawns" of the United States and Israel.According to the Associated Press, the Nepalese Prime Ministers office said the floods have killed at least 95 people.On August 26th, Revolution Medicines pancreatic cancer drug Daraxonrasib received approval from US regulatory agencies, becoming the first drug to target one of the key molecular mechanisms of pancreatic cancer. The drug, marketed under the name Rasonque, is considered one of the most significant breakthroughs in pancreatic cancer treatment in recent years. According to data from the US Food and Drug Administration (FDA), a late-stage clinical trial announced in May showed that Daraxonrasib nearly doubled the typical survival of patients with a highly aggressive form of pancreatic cancer, reaching 13.2 months, while the average survival for patients receiving chemotherapy (the current standard of care) was only 6.7 months.